

# POST-ESMO/WCM MEETING MELANOOM

16 november



MADRID, SPAIN  
8 - 12 SEPTEMBER 2017



BRISBANE, AUSTRALIA  
18 - 21 OCTOBER 2017

18.30 - 18.45	<b>Melanoma &amp; Surgery</b> <i>The latest study data updates</i>	A. van Akkooi
	- MSLT-2 study & DECOG-SLT results	
18.45 - 19.15	<b>Adjuvant Melanoma</b> <i>The latest study data updates</i>	A. van Akkooi
	- BRIM-8 - CHECKMATE-238 - COMBI-AD - OpACIN survival and biomarkers	
	Does adjuvant treatment have a positive effect on overall survival?	
19.15 - 19.30	<b>Break</b>	
19.30 - 19.45	<b>Neo-Adjuvant</b> <i>The latest study data updates</i>	A. van Akkooi
19.45 - 19.55	<b>Discussion</b>	H. van Thienen & A. van Akkooi
19.55 - 20.35	<b>Advanced Melanoma</b> <i>Combination &amp; Triple therapies, what is new in TT and IO?</i>	H. van Thienen
	- COLUMBUS - KEYNOTE-022 - COMBI-i - Immuno-Oncology combinations in advanced melanoma	
20.35 - 20.50	<b>Break</b>	
20.50 - 21.10	<b>Treatment sequencing in melanoma</b> <b>Continuous or intermittent?</b>	H. van Thienen
21.10 - 21.20	<b>Discussion &amp; final remarks</b>	H. van Thienen & A. van Akkooi

0917TAF817298

